NPT200-11 was well tolerated in 55 volunteers after oral administration.
Neuropore Therapies (NPT™) organizes 2016 Society for Neuroscience Satellite Event, "Targeting alpha-synuclein as a disease-modifying treatment for PD & synucleinopathies". November 13, 2016 in San Diego, CAClick here for more information.
Report in Scientific Reports, describes the use of non-invasive retinal imaging in animal models as a tool to monitor the fate of α-synuclein accumulation in the CNS.
Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.
Learn More See All Videos